CD8A and neoplasm: Deeper characterization of the cell types (Supplementary Fig. S19e) revealed enrichment in the postNI tumors of SPP1 + tumor-associated macrophages (TAMs), which can drive immunotherapy resistance by dysregulating CD8 + T cells25, and remodel the TME to support tumor cell aggressiveness correlating with worse prognosis26.